RXi Pharmaceuticals Corporation (RXII)
-OTC Markets 0.20 0.00(0.00%) May 21, 3:59PM EDT
| Prev Close: | 0.20 |
|---|
| Open: | 0.19 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.19 - 0.20 |
|---|
| 52wk Range: | 0.05 - 0.36 |
|---|
| Volume: | 336,907 |
|---|
| Avg Vol (3m): | 1,452,040 |
|---|
| Market Cap: | 67.63M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- RXI PHARMACEUTICALS CORP FinancialsEDGAR Online Financials(Tue, May 21)
- RXi Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare ConferencePR Newswire(Mon, May 20)
- RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2013Marketwired(Wed, May 15)
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Wed, May 15)
- RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu, May 9)
- RXi Pharmaceuticals to Present at IBC's 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics ConferencePR Newswire(Thu, May 9)
- RXi Pharmaceuticals to Present at the 2013 ARVO Annual MeetingBusiness Wire(Tue, Apr 30)
- RXi Pharmaceuticals Announces Investor and Analyst SymposiumBusiness Wire(Mon, Apr 29)
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Wed, Apr 24)
- RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of DirectorsBusiness Wire(Mon, Apr 22)
- RXi Pharmaceuticals CEO reports ‘nearly flawless’ first yearat bizjournals.com(Fri, Mar 29)
- RXi Pharmaceuticals Reports Full Year 2012 Financial ResultsBusiness Wire(Fri, Mar 29)
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Fri, Mar 29)
- RXI PHARMACEUTICALS CORP Files SEC form 10-K, Annual ReportEDGAR Online(Fri, Mar 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 450.87 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
RXi Pharmaceuticals Corporation discovers, develops, and commercializes therapies based on its RNAi platform. It provides RXI-109, a self-delivering RNAi compound (sd-rxRNA) for the reduction of dermal scarring in planned surgeries, as well as red...
View More 
0.34%